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The human body consists of hundreds of different cell types, each with a different form and function. 
A large body of evidence, including Nobel-prize winning work on generation of pluripotent stem cells, 
suggests that proteins known as transcription factors are master regulators of cell type identity that, 
by directly binding to DNA, function to switch on specific sets of genes in each cell type. One such 
transcription factor, MyoD, which was first discovered here at the Fred Hutch in the laboratory of the 
late Dr. Harold Weintraub almost 30 years ago, is a master regulator of muscle cells as it can 
convert non-muscle cells such as fibroblasts into skeletal muscle, in a process known as 
transdifferentiation. Since its discovery, other transcription factors with similar cell fate-determining 
functions have been identified. For instance, NeuroD2 can transdifferentiate cells into neurons. Both 
MyoD and NeuroD2 are part of a family of transcription factors that contain a basic-helix-loop-helix 
(bHLH) domain that is required for DNA binding and both bind to highly similar target sequences. 
Previous studies in Dr. Stephen Tapscott’s Laboratory (Clinical Research and Human Biology 
Divisions) used chromatin immunoprecipitation followed by next-generation DNA sequencing (ChIP-
seq) to show that while MyoD and NeuroD2 can bind to shared DNA sites, they also bind DNA sites 
that are specific to each factor, termed private sites, that are highly correlated with cell type specific 
gene activation (Fong et al.,2012). 
However, it remained unclear which domains of MyoD and NeuroD2 were important for cell type 
determination. A new study by the Tapscott lab, led by research associate Dr. Abraham Fong and 
published in Cell Reports, addressed this question by generating a chimeric transcription factor 
wherein the bHLH domain of MyoD was replaced with the bHLH domain of NeuroD2. This chimera, 
MyoD (NeuroD2-bHLH), exhibited strong gene activation of a reporter containing a pair of NeuroD2 
private sites and weak activation of a reporter containing a pair of either one of the shared sites or of 
the MyoD private sites, similar to NeuroD2 itself. This gene activation pattern correlated with DNA-
binding affinity, as demonstrated by in vitro gel shift assays. 
Next, to assay the DNA-binding properties of the chimera in cells, the authors performed ChIP-seq 
experiments with NeuroD2, MyoD and MyoD (NeuroD2-bHLH) in a mouse embryonal carcinoma cell 
line (P19). Indeed, discriminative motif enrichment analysis showed that MyoD (NeuroD2-bHLH) 
acquired the DNA-binding properties of NeuroD2. Next-generation sequencing of RNA (RNA-seq) of  
 
May 18, 2015 SCIENCE SPOTLIGHT 
 
2 Volume 5, Issue 5 | Fred Hutchinson Cancer Research Center 
 
 
P19 cells transduced with either NeuroD2, MyoD or MyoD (NeuroD2-bHLH), revealed that the 
chimera activated both neuronal and muscle genes. These studies were corroborated by examining 
both neuronal and muscle markers either in P19 cells or in zebrafish embyros that had been 
transduced or injected with the chimera, respectively. 
Finally, the authors addressed the question of why the chimera still bound to a subset of muscle 
genes. To this end, they performed discriminative motif enrichment analysis of the DNA region 
surrounding sites bound both by the chimera and MyoD, but not NeuroD2, which revealed an 
enrichment for binding sites for homeodomain transcription factors of the PBX/MEIS family. 
Intriguingly, a PBX/MEIS complex had been previously shown by the Tapscott lab to be required for 
full activation of 10% of MyoD target genes. Strikingly, P19 cells transduced with a modified chimera 
in which the PBX/MEIS interaction domain was mutated essentially behaved as a dedicated 
neurogenic factor and lost the ability to activate key muscle genes such as myogenin. 
"It was initially surprising to us that retargeting MyoD to the NeuroD2 binding sites was sufficient to 
convert it to a master regulator of neurogenesis, but now this helps us understand recent reports 
showing that spindle cell rhabdomyosarcomas have a mutation in MyoD that changes its binding 
specificity to Myc sites and makes it oncogenic. So by changing the MyoD DNA binding specificity 
we can change it from a myogenic factor to either a neurogenic factor or an oncogenic factor. This 
suggests a direct approach to tissue engineering as well as an understanding of how new 
transcriptional programs can arise during evolution", said Dr. Stephen Tapscott. In conclusion, this 
report showed that the DNA binding specificity of bHLH transcription factors largely determines their 
transcriptional output, which warrants similar studies of other transcription factor families to establish 
the generality of this concept. 
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Image provided by Dr. Stephen Tapscott. 
The transcription factor MyoD normally determines muscle fate 
by binding to its private DNA sites (red). Swapping MyoD’s 
DNA-binding domain with a similar yet distinct domain in 
NeuroD2 converts MyoD into a neuron-determining factor, by 
retargeting the MyoD-NeuroD2 chimera to NeuroD2’s private 
DNA sites (blue). 
 
